Lv0
0 积分 2025-10-13 加入
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
2天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
3天前
已完结
Targeting cancer with small molecule pan-KRAS degraders
8天前
已完结
Lessons learned from Myc/Max/Mad knockout mice
1个月前
已完结
c-myc protein expression in untransformed fibroblasts
1个月前
已关闭
How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations
2个月前
已完结
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
6个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
10个月前
已完结
皖公网安备34019202002308
